Subject: Cancer Treatment | Research Article | Ewing Sarcoma | Anatomy | Research Design | Case Series | Cardiovascular Physiology | Oncology | Leiomyosarcoma | Biological Tissue | Soft Tissues | Endocrine Physiology | Cancers and Neoplasms | Sarcomas | Biology and Life Sciences | Growth Factors | Angiogenesis | Developmental Biology | Research and Analysis Methods | Clinical Research Design | Physiology | Medicine | Q | R | Science | Medicine and Health Sciences | Endocrinology
Background Patients with metastatic sarcoma who progress on vascular endothelial growth factor receptor inhibitors (VEGFRi) have limited treatment options. Upregulation of the mTOR pathway has been demonstrated to be a means of resistance to targeted VEGFRi in metastati... View more
7 Mir O, Brodowicz T, Wallet J, Italiano A, Cesne AL, et al. (2015) Activity of regorafenib (RE) in leiomyosarcomas (LMS) and other types of soft-tissue sarcomas (OTS): Results of a double-blind, randomized placebo (PL) controlled phase II trial. 2015 ASCO Annual Meeting. Chicago, IL: Journal of Clinical Oncology.